CC-10015

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameCC-10015
Drug Alias NameCC-10015
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunomodulatorsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsLupus Erythematosus, SystemicSarcoidosisMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesCelgene Corp
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicMultiple Myeloma
Inactive IndicationsSarcoidosis

Other Information

ATC CodeN/A
Related LinksN/A